Analysts Offer Predictions for Compass Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:CMPX)

Posted by Defense World Staff on Mar 18th, 2023

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) – Equities research analysts at Wedbush issued their Q1 2023 EPS estimates for shares of Compass Therapeutics in a note issued to investors on Wednesday, March 15th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.12) per share for the quarter. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.47) per share. Wedbush also issued estimates for Compass Therapeutics’ Q2 2023 earnings at ($0.13) EPS, Q3 2023 earnings at ($0.14) EPS and Q4 2023 earnings at ($0.15) EPS.

Several other equities research analysts also recently commented on CMPX. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Thursday. EF Hutton Acquisition Co. I initiated coverage on Compass Therapeutics in a report on Friday, December 16th. They issued a “buy” rating and a $10.30 price objective for the company. Jefferies Financial Group assumed coverage on shares of Compass Therapeutics in a research report on Tuesday, January 31st. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Stifel Nicolaus began coverage on Compass Therapeutics in a research note on Thursday, January 26th. They issued a “buy” rating and a $9.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $9.05.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $3.40 on Friday. The firm has a 50-day moving average of $4.00 and a 200 day moving average of $3.84. Compass Therapeutics has a 1 year low of $1.25 and a 1 year high of $5.65. The stock has a market cap of $429.05 million, a P/E ratio of -8.10 and a beta of 0.93.

Insider Activity

In other news, CEO Thomas J. Schuetz bought 20,000 shares of the firm’s stock in a transaction on Tuesday, January 24th. The stock was acquired at an average cost of $4.19 per share, with a total value of $83,800.00. Following the transaction, the chief executive officer now directly owns 5,451,873 shares in the company, valued at approximately $22,843,347.87. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Thomas J. Schuetz bought 20,000 shares of the company’s stock in a transaction on Tuesday, January 24th. The shares were acquired at an average price of $4.19 per share, with a total value of $83,800.00. Following the transaction, the chief executive officer now owns 5,451,873 shares of the company’s stock, valued at $22,843,347.87. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Thomas J. Schuetz purchased 10,000 shares of Compass Therapeutics stock in a transaction dated Friday, March 10th. The stock was bought at an average cost of $3.37 per share, with a total value of $33,700.00. Following the completion of the transaction, the chief executive officer now owns 6,021,873 shares in the company, valued at approximately $20,293,712.01. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 90,000 shares of company stock valued at $355,300. 29.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CMPX. Jane Street Group LLC purchased a new stake in Compass Therapeutics in the third quarter valued at approximately $33,000. Bank of New York Mellon Corp purchased a new stake in Compass Therapeutics during the third quarter worth $55,000. UBS Group AG boosted its holdings in Compass Therapeutics by 63.5% during the fourth quarter. UBS Group AG now owns 11,819 shares of the company’s stock worth $59,000 after buying an additional 4,591 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at about $75,000. Finally, Boothbay Fund Management LLC purchased a new position in Compass Therapeutics during the fourth quarter worth approximately $86,000. Institutional investors and hedge funds own 54.27% of the company’s stock.

About Compass Therapeutics

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.